Estatísticas para RT 1654 2019 - Pembrolizumabe para Carcinoma Urotelial - NATJUS TJMG

Total de visitas

views
RT 1654 2019 - Pembrolizumabe para Carcinoma Urotelial - NATJUS TJMG 5

Total visitas por mês

views
September 2024 0
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0

Visitas Arquivos

views
RT 1654.pdf 1